Get the Daily Brief
Latest Biotech News
Advances in Cell Therapy Manufacturing and Clinical Trials
Cidara Therapeutics completed a $402.5 million public offering to fund its Cloudbreak platform for developing drug-Fc conjugates. Ionis Pharmaceuticals and Biogen reported positive Phase 1 results...
Vor Bio's Strategic Pivot into Autoimmune Therapeutics
Vor Biopharma, after significant restructuring, secured $175 million in private equity and in-licensed telitacicept from China’s RemeGen. This dual-action fusion protein targets BAFF and APRIL...
New Study Illuminates PIEZO2’s Role in Heart Vessel Formation
Research led at Max Delbrück Center reveals PIEZO2 ion channels govern coronary vessel development in embryos, extending their known function beyond mechanosensation. Mouse models show both loss...
Plastic Waste Recycling via Inline Nuclear Magnetic Resonance
A novel solid-state NMR technique developed by a team at Dalian Institute of Chemical Physics utilizes 1H-13C FSLG-HETCOR spectroscopy to precisely characterize complex plastic waste mixtures....
Cutting-Edge Liver Organoids with Vascular Networks
Cincinnati Children’s Hospital researchers have engineered liver organoids capable of self-generating specialized blood vessels resembling human liver vasculature. Utilizing a multilayered gel...
Kymera’s oncology collaborations evolve with Gilead, Sanofi shifts focus
Kymera Therapeutics has entered a significant agreement with Gilead Sciences to jointly develop oral molecular glue degraders targeting CDK2 for solid tumors, including breast cancer. The deal...
DeepMind Unveils AlphaGenome to Model Gene Regulation from DNA
Google’s DeepMind has released AlphaGenome, an AI model designed to predict the effects of small DNA sequence changes on gene regulation. Building on the success of AlphaFold in protein structure...
Adaptive Biotechnologies Benefits from NCCN's Updated Multiple Myeloma Guidelines
Adaptive Biotechnologies’ stock surged following the National Comprehensive Cancer Network’s updated multiple myeloma guidelines, which now recommend baseline clonotype identification at diagnosis...
Gilead Ends RSV Antiviral Trials Citing Low Infection Rates
Gilead Sciences has terminated two Phase 2 trials of its RSV antiviral candidate obeldesivir due to lower-than-expected infection rates during the recent RSV season, which impaired the ability to...
Novartis and ProFound Therapeutics Partner on Cardiovascular Protein Targets
Novartis has signed a four-year strategic collaboration with ProFound Therapeutics, combinigng ProFound's advanced protein identification platform with Novartis’ cardiovascular expertise to...
Altimmune Posts Mixed Phase IIb Results in Fatty Liver Disease; Shares Plunge
Altimmune reported top-line data from its Phase IIb Impact study of pemvidutide, a GLP-1/glucagon dual receptor agonist, in metabolic dysfunction-associated steatohepatitis (MASH). The therapy met...
Mount Sinai Applies Wearable Tech to Link IBD Inflammation and Sleep Disruption
Researchers at Mount Sinai have utilized wearable devices such as smartwatches and fitness trackers in a longitudinal study to objectively measure sleep patterns in patients with inflammatory...
Breakthrough in Liver Organoids Generating Functional Blood Vessels
Scientists from Cincinnati Children’s Hospital Medical Center have engineered liver organoids capable of forming their own specialized blood vessel networks resembling human liver vasculature....
Breakthrough AI Model, NeoPred, Enhances Preoperative Response Prediction in Lung Cancer
A research team at Guangzhou Medical University has developed NeoPred, a novel AI platform combining dual-phase CT imaging and clinical data to predict pathological responses of non-small cell...
Vor Biopharma Shifts Focus to Autoimmune Diseases with New CEO and $175M Funding
Vor Biopharma, following significant workforce reductions and strategic review, has pivoted from oncology to autoimmune disease therapies by licensing telitacicept—a dual-target fusion protein...
AI Advances Reshape Drug Discovery and Genomic Research
Artificial intelligence continues to revolutionize biotechnology, with major strides in drug design, genomics, and medical imaging. Google DeepMind’s AlphaGenome introduces a unified AI model...
Autoimmune Disease Focus: Vor Bio’s Strategic Pivot and New Funding
Vor Biopharma has dramatically shifted strategy from oncology to autoimmune disorders, securing $175 million in private equity to support this transition. The company licensed global rights to...
Vaccine Advisory Shakeup Sparks Debate on Immunization Policy
The U.S. CDC’s Advisory Committee on Immunization Practices (ACIP) underwent a controversial reconstitution after Health and Human Services Secretary Robert F. Kennedy Jr. dismissed all prior...
Cutting-Edge Regenerative Medicine and Tissue Engineering Developments
Recent breakthroughs in regenerative biology and therapeutic innovation spotlight promising avenues for tissue repair and organoid technology. Researchers identified a dormant gene switch in mice...
Major Biopharma Financial Moves and Leadership Changes
Significant leadership and financing maneuvers are reshaping the biopharma landscape. Incyte appointed Bill Meury as CEO, replacing Hervé Hoppenot after 11 years, with hopes to diversify beyond...